ApoE-Corona oncolytic adenovirus nanoparticles enable blood-brain barrier penetration for glioblastoma immunotherapy

Area of Science:

• Nanotechnology
• Oncolytic Virus Therapy
• Cancer Immunotherapy

Background:

• Intravenous oncolytic adenovirus (OA) delivery faces limitations in treating glioblastoma (GBM) due to poor blood-brain barrier (BBB) penetration and glioma targeting.
• Developing effective strategies for targeted delivery of OA to GBM is crucial for improving therapeutic outcomes.

Purpose of the Study:

• To design and evaluate oncolytic adenovirus nanoparticles (OA@Aβ-am NPs) for efficient and targeted delivery to GBM.
• To investigate the dual targeting capability of OA@Aβ-am NPs for both the BBB and GBM.
• To assess the therapeutic efficacy and immunomodulatory effects of OA@Aβ-am NPs in GBM models.

Main Methods:

• Construction of OA@Aβ-am NPs using OA as the core, modified amyloid beta peptide (Aβ-am) for ApoE accumulation, and targeting of LDLR-associated protein 1 (LRP1).
• In vitro and in vivo studies to evaluate the targeting efficiency, BBB penetration, and GBM accumulation of OA@Aβ-am NPs.
• Assessment of anti-tumor immune responses, including conversion of "cold" GBM to "hot" tumors and induction of immunogenic cell death (ICD).

Main Results:

• OA@Aβ-am NPs demonstrated excellent targeting ability and enhanced BBB penetration.
• The nanoparticles effectively accumulated in glioma sites, prolonging survival in GBM-bearing mice.
• OA@Aβ-am NPs successfully induced anti-tumor immune responses and immunogenic cell death in GBM.

Conclusions:

• The developed OA@Aβ-am NP platform provides a promising strategy for targeted oncolytic adenovirus therapy in GBM.
• This approach enhances the therapeutic potential of OA by overcoming delivery barriers and stimulating anti-tumor immunity.
• OA@Aβ-am NPs represent a significant advancement in developing effective immunotherapies for glioblastoma.